financetom
Business
financetom
/
Business
/
US sugar demand up, corn syrup down, as consumers pick less processed foods, report says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US sugar demand up, corn syrup down, as consumers pick less processed foods, report says
Jul 30, 2026 12:42 PM

NEW YORK, July 30 (Reuters) - Demand for sugar in the U.S. grew modestly along with the population, while use of high fructose corn syrup fell, a report said on Thursday, suggesting Americans may be trying harder to avoid highly processed foods than to cut back on sugar.

Cane and beet sugar demand in the U.S. rose 0.6% in the first half of the 2025/26 marketing year that started in October, while HFCS deliveries fell 3.5% in the same period, said a report by U.S. rural lender CoBank based on compiled data from the Department of Agriculture (USDA). 

"While concerns about sugar consumption dominate headlines, rising USDA delivery data suggest demand for cane and beet sugar remains firmly intact," the report said, adding that wholesale grocers and food distributors were among the sectors where sugar demand grew more.

"Food manufacturers and consumers continue to favor natural sweeteners over more highly processed alternatives, as sugar and HFCS delivery trend lines make clear," the report said.

The 0.6% growth in sugar demand was in line with the annual population increase in the U.S. which was 0.5% in 2025. 

Three out of four U.S. consumers said they want to limit or completely avoid sugar in a 2025 survey, according to the International Food Information Council.

The CoBank report said the Make America Healthy Again (MAHA) movement showed long-term risks for the sugar industry, as did the prospect of increased use of GLP-1 drugs to reduce obesity.

"Some projections suggest grocery basket sizes could decline by as much as 31% among active users (of GLP). Sweetened foods and beverages are unlikely to be uniquely affected, but they will still face lower demand if consumers generally eat less," the report said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mattr Signs Definitive Agreement to Sell Its Brazilian Pipe Coating Business to Vallourec For US$17.5 Million
Mattr Signs Definitive Agreement to Sell Its Brazilian Pipe Coating Business to Vallourec For US$17.5 Million
Sep 16, 2024
07:44 AM EDT, 09/16/2024 (MT Newswires) -- Mattr Corp. ( MTTRF ) on Monday entered into a definitive agreement to sell its subsidiary, Thermotite do Brazil, to Vallourec Tubular Solutions, a subsidiary of Vallourec S.A.. A statement noted Thermotite provides thermal insulation pipe coating services to the offshore oil and gas industry from its plant in Serra, Brazil and is...
Penumbra Gets CE Mark for Computer Assisted Vacuum Thrombectomy Technologies
Penumbra Gets CE Mark for Computer Assisted Vacuum Thrombectomy Technologies
Sep 16, 2024
10:13 AM EDT, 09/16/2024 (MT Newswires) -- Penumbra (PEN) said Monday it received the CE Mark in Europe for its computer-assisted vacuum thrombectomy technologies Lightning Flash 2.0 and Lightning Bolt 7. The technologies are used to remove clots in the vascular system, the company said. Penumbra said the products will assure doctors in Europe that computer-assisted vacuum thrombectomy is a...
SunCar Technology's H1 Net Loss Widens; Revenue Rises
SunCar Technology's H1 Net Loss Widens; Revenue Rises
Sep 16, 2024
07:42 AM EDT, 09/16/2024 (MT Newswires) -- SunCar Technology ( SDA ) reported an H1 net loss Monday of $0.67 per diluted share, wider than the $0.04 loss a year earlier. Analyst estimates were not available for comparison. Revenue for the six months ended June 30 was $203.1 million, up from $159.4 million a year earlier. ...
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Immatics Ends Collaboration With Bristol-Myers to Co-Develop IMA401 Targeting Melanoma-Associated Antigen
Sep 16, 2024
07:59 AM EDT, 09/16/2024 (MT Newswires) -- Immatics ( IMTX ) said Monday it has ended its partnership with Bristol-Myers Squibb ( BMY ) to co-develop IMA401, targeting melanoma-associated antigen, because of current portfolio prioritization within the latter. The current partnership and license agreement, initially signed in 2021, will end on Dec. 12, the company added. Under the terms, Immatics...
Copyright 2023-2026 - www.financetom.com All Rights Reserved